Trial Outcomes & Findings for Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma (NCT NCT05002621)
NCT ID: NCT05002621
Last Updated: 2026-03-18
Results Overview
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples for bulk RNA sequencing. Paired differential expression (DE) gene analysis was performed comparing baseline gene expression versus 12 weeks post initiation of mepolizumab.
COMPLETED
20 participants
12 weeks post initiation of mepolizumab
2026-03-18
Participant Flow
20 subjects were recruited.
No significant events occurred between the enrollment and assignment of participants to an arm or group.
Participant milestones
| Measure |
Severe Eosinophilic Asthma
This study involved twenty adult (≥18yo) individuals with a diagnosis of severe eosinophilic asthma (SEA) who had been prescribed mepolizumab during their course of routine clinical care.
|
|---|---|
|
Overall Study
STARTED
|
20
|
|
Overall Study
COMPLETED
|
20
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Severe Eosinophilic Asthma
n=20 Participants
This study involved twenty adult (≥18yo) individuals with a diagnosis of severe eosinophilic asthma (SEA) who had been prescribed mepolizumab during their course of routine clinical care.
|
|---|---|
|
Age, Continuous
|
51.5 years
n=20 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=20 Participants
|
|
peak absolute eosinophil count
|
880 cell count
n=20 Participants
|
PRIMARY outcome
Timeframe: 12 weeks post initiation of mepolizumabPeripheral blood mononuclear cells (PBMCs) were isolated from blood samples for bulk RNA sequencing. Paired differential expression (DE) gene analysis was performed comparing baseline gene expression versus 12 weeks post initiation of mepolizumab.
Outcome measures
| Measure |
12 Weeks Post Initiation of Mepolizumab
n=20 Participants
All 20 participants had peripheral blood mononuclear cells (PBMCs) isolated from blood samples for bulk RNA sequencing at baseline and at 12 weeks post initiation of mepolizumab. Paired differential expression (DE) gene analysis was performed comparing baseline gene expression versus 12 weeks post initiation of mepolizumab.
|
|---|---|
|
Differentially Expressed Genes
|
149 differentially expressed gene
|
Adverse Events
Severe Eosinophilic Asthma
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place